While GNBT is about 15% the MC of CYDY, they seem like a good comparison in some ways of what CYDY can expect with a coronavirus deal and share price response as they are also listed on the OTCQB (currently up 87%).

Quote:

---

The terms of the contract, which have been agreed to in writing by both parties, include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced.

---

https://markets.businessinsider.com/news/stoc...1028946781

I would be okay with a $5-10M upfront/milestone deal for coronavirus and 25%+ royalty with no trial or approval expenses. This would bring in much needed awareness, a little money and establish a relationship to build upon for larger deals with cancer, NASH, HIV, etc.